Everolimus/Lanreotide Prolongs PFS in Unresectable/Recurrent GEP-NETs
Everolimus plus lanreotide elicited a PFS of 29.7 months compared with 11.5 months from everolimus monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.
Related Articles
Program Guide – ASCO Meeting Program Guide
Jonathan Strosberg H. Lee Moffitt Cancer Center and Research Institute Jonathan Strosberg , Anna Koumarianou , Rachel Riechelmann , Jorge Hernando , Sara Cingarlini ,…
Nivolumab Plus Chemo Shows Long-Term OS Benefit in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer
Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.
Laura, Marginal Zone Lymphoma
Laura, Marginal Zone Lymphoma In late 2018, I was 60 years old and had been losing weight and working on getting into better shape. At…
A Phase 1 Clinical Trial of NKTR-255 With CD19-22 CAR T-Cell Therapy for Refractory B-Cell Acute Lymphoblastic Leukemia
Researchers at Stanford University have conducted a phase 1 clinical trial (#NCT03233854) evaluating the combination of a bispecific chimeric antigen receptor (CAR) T-cell therapy targeting…
Overview of the DESTINY-Breast12 Study
Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its…
Cancer Incidence Continues to Rise, Especially in Women Younger Than 65
Of note, lung cancer incidence was higher among women younger than 65 compared with their male counterparts in 2021.
Glucarpidase improves recovery after chemotherapy-induced kidney toxicity
Glucarpidase significantly improved kidney function for patients who developed acute kidney injury from high-dose methotrexate, according to results of a large, multicenter observational study.Glucarpidase (Voraxaze,…
First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC
OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.
JNCCN 360 – Advanced Skin Cancers – Mehran Yusuf, MD, on Treating Merkel Cell Carcinoma: A Radiation Oncology Perspective
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
Honoring Excellence: Q and A with Dr. Cassandra Fritz of the Washington University in St. Louis Internal Medicine Residency Program
A Q and A with Dr. Cassandra Fritz from the WashU internal medicine program. The program is receiving a 2025 ACGME Barbara Ross-Lee, DO DEI…
